// App-Quantinova.ai

: Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress.

Researchers

Presenter

  • Ashish M. Kamat

Principal Investigators

  • Gary D. Steinberg

  • Brant Allen Inman

  • Max R. Kates

  • Edward M. Uchio

  • Sima P. Porten

  • Morgan Roupret

  • Joan Redorta

  • James W.F. Catto

  • Girish S. Kulkarni

  • Thomas Powles

  • Mark Tyson

  • Gabriel P. Haas

  • Yao Yu

  • Matthew Birrenkott

  • Yair Lotan

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Autonomous University of Spain, Barcelona, Spain

  • Duke University Medical Center, Durham, NC

  • Sheffield Children's Hospital, Sheffield, United Kingdom

  • University of California, San Francisco, San Francisco, CA

  • University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • UTSouthwestern Medical Center, Dallas, TX

  • Bart's Cancer Institute, London, United Kingdom

  • Johns Hopkins Medicine, Baltimore, MD

  • Mayo Clinic Arizona, Phoenix, AZ

  • Hôpital Pitié-Salpêtrière,Paris,France

  • NYU Department of Urology, Perlmutter Cancer Center, New York, NY

  • University of California, Irvine, Fullerton, CA

Locations

  • France

  • Canada

  • Spain

  • United Kingdom

  • United States

Companies

  • Astellas Pharma Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Enfortumab vedotin

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Expansion Study

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT05014139

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved